Teachers Retirement System of The State of Kentucky Grows Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Teachers Retirement System of The State of Kentucky raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 71.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 76,115 shares of the biopharmaceutical company's stock after buying an additional 31,665 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in TG Therapeutics were worth $3,001,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in TGTX. Clearbridge Investments LLC purchased a new stake in TG Therapeutics during the fourth quarter valued at about $55,237,000. Raymond James Financial Inc. purchased a new stake in TG Therapeutics during the 4th quarter valued at about $14,508,000. Norges Bank purchased a new stake in TG Therapeutics during the 4th quarter valued at about $12,085,000. Penn Capital Management Company LLC bought a new position in TG Therapeutics during the 4th quarter worth approximately $10,577,000. Finally, First Trust Advisors LP increased its stake in TG Therapeutics by 871.7% in the 4th quarter. First Trust Advisors LP now owns 275,496 shares of the biopharmaceutical company's stock worth $8,292,000 after purchasing an additional 247,145 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, TG Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $43.80.

Insider Activity at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares in the company, valued at $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.64% of the company's stock.

TG Therapeutics Trading Down 0.1%

NASDAQ:TGTX opened at $37.37 on Wednesday. The company has a 50 day simple moving average of $36.41 and a two-hundred day simple moving average of $35.58. The company has a market cap of $5.93 billion, a PE ratio of 155.71 and a beta of 1.91. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. TG Therapeutics, Inc. has a 12 month low of $16.65 and a 12 month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same period in the prior year, the company posted ($0.07) earnings per share. The firm's quarterly revenue was up 90.4% on a year-over-year basis. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.